Abstract
The MERIT study was a single-arm, phase II clinical trial of nivolumab for the second- or third-line treatment of patients with malignant pleural mesothelioma in Japan. MERIT confirmed that PD-1 inhibition has activity in mesothelioma and led to the regulatory approval of nivolumab for the treatment of mesothelioma in Japan.
Cite
CITATION STYLE
APA
Mansfield, A. S., & Zauderer, M. G. (2019). Nivo-lution in mesothelioma. Clinical Cancer Research, 25(18), 5438–5440. https://doi.org/10.1158/1078-0432.CCR-19-1836
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free